PharmaShots Weekly Snapshots (December 20 - 23, 2021)
Published: Dec 23, 2021 | Tags: Novartis, Cosentyx, US FDA, Enthesitis-Related Arthritis, Psoriatic Arthritis, Sensoready, US, China
Published: Dec 23, 2021 | Tags: Gilead, Veklury, Remdesivir, COVID-19, P-III, PINETREE Study, IND, US, FDA
Published: Dec 23, 2021 | Tags: DURECT, Innocoll, Posimir, Bupivacaine Solution, US, Commercial Licensing Agreement
Published: Dec 23, 2021 | Tags: Aerogen Pharma, Nuance Pharma, Respiratory Distress Syndrome, AeroFact, Alveofact, Nasal Delivery System, China
Published: Dec 23, 2021 | Tags: Akeso, Dawnrays Biotechnology, Ebronucimab, PCSK9 mAb, P-III Trial, Hypercholesterolemia, Mixed Hyperlipidemia
Published: Dec 23, 2021 | Tags: Pfizer, US FDA, Emergency Use Authorization, Paxlovid, COVID-19, EPIC-HR study, Nirmatrelvir, Ritonavir
Published: Dec 22, 2021 | Tags: Pfizer, Vyndaqel, Vyndamax, P-III, ATTR-ACT Trial, Transthyretin Amyloid Cardiomyopathy
Novartis to Acquire Gyroscope Therapeutics for Ocular Gene Therapy to Treat Geographic Atrophy
Published: Dec 22, 2021 | Tags: Novartis, Acquire, Gyroscope Therapeutics, Ocular Gene Therapy, Geographic Atrophy
Gilead Reports the US FDA's Clinical Hold of Lenacapavir for the Treatment of HIV
Published: Dec 22, 2021 | Tags: Gilead, US, FDA, Clinical Hold, Lenacapavir, HIV
Novaliq Reports Results of CyclASol in P-III (ESSENCE-2) Trial for the Treatment of Dry Eye Disease
Published: Dec 22, 2021 | Tags: Novaliq, CyclASol, P-III, ESSENCE-2 Trial, Dry Eye Disease
GSK Expands its Collaboration with Ligand to Develop Genetically-Validated Targets for Neurological Diseases Gilead, US, FDA, Clinical Hold, Lenacapavir, HIV
Published: Dec 22, 2021 | Tags: GSK, Ligand, Genetically-Validated, Targets, Neurological Diseases
Published: Dec 22, 2021 | Tags: Karyopharm, Menarini, Nexpovio, Selinexor, Oncology
Gilead’s Veklury (remdesivir) Receives EC’s Approval for the Treatment of COVID-19
Published: Dec 21, 2021 | Tags: Gilead, Veklury, remdesivir, EC, Approval, COVID-19
Lilly Reports Results of Lebrikizumab in P-III (Adhere) Trial for the Treatment of Atopic Dermatitis
Published: Dec 21, 2021 | Tags: Lilly, Lebrikizumab, P-III, Adhere Trial, Atopic Dermatitis
Sanofi to Acquire Amunix for Transformative T-Cell Engagers and Cytokine Therapies to Treat Cancer
Published: Dec 21, 2021 | Tags: Sanofi, Acquire, Amunix, Transformative T-Cell Engagers, Cytokine Therapies, Cancer
ViiV Healthcare’s Apretude (cabotegravir) Receives US FDA’s Approval for the Prevention of HIV
Published: Dec 21, 2021 | Tags: ViiV Healthcare, Apretude, cabotegravir, US, FDA, Approval, HIV
Published: Dec 21, 2021 | Tags: Cytokinetics, Ji Xing, Omecamtiv Mecarbil, HFrEF, Greater China
Novartis Signs a Multiple Agreement with BeiGene for Ociperlimab to Treat Solid Tumor
Published: Dec 21, 2021 | Tags: Novartis, BeiGene, Ociperlimab, Solid Tumor
Published: Dec 20, 2021 | Tags: Lineage, Genentech, OpRegen RPE Cell Therapy, Ocular Disorders
Published: Dec 20, 2021 | Tags: Novartis, Ligelizumab, QGE031, P-III, PEARL 1, 2, Studies, Chronic Spontaneous Urticaria
Published: Dec 20, 2021 | Tags: bluebird bio, US, FDA, BLA, Priority Review, Lenti-D, elivaldogene autotemcel, Cerebral Adrenoleukodystrophy
Published: Dec 20, 2021 | Tags: GBT, Oxbryta, voxelotor, CHMP, Hemolytic Anemia, Sickle Cell Disease
GSK and Vir’s Xevudy (sotrovimab) Receive EC's Marketing Authorization for the Treatment of COVID-19
Published: Dec 20, 2021 | Tags: GSK, Vir, Xevudy, sotrovimab, EC, Marketing Authorization, COVID-19
Published: Dec 20, 2021 | Tags: Janssen, Dyadic, Therapeutic Protein Candidates, C1 Platform
Related Post: PharmaShots Weekly Snapshots (December 13 - 17, 2021)
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com